CG Oncology (NASDAQ:CGON) Earns Buy Rating from HC Wainwright

CG Oncology (NASDAQ:CGON)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $75.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 120.91% from the stock’s previous close.

Several other research analysts also recently weighed in on the company. Morgan Stanley assumed coverage on CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $55.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of CG Oncology in a report on Tuesday, February 20th. They set a “neutral” rating and a $42.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price target on shares of CG Oncology in a research report on Thursday, May 2nd.

CG Oncology Stock Performance

CGON stock opened at $33.95 on Monday. CG Oncology has a 52-week low of $28.55 and a 52-week high of $50.23. The stock’s 50-day moving average price is $39.17.

Hedge Funds Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently modified their holdings of CGON. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology during the 1st quarter worth approximately $492,000. Capstone Investment Advisors LLC purchased a new position in CG Oncology during the first quarter worth approximately $806,000. Finally, TimesSquare Capital Management LLC acquired a new position in CG Oncology during the first quarter worth $9,837,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.